Please use this identifier to cite or link to this item: https://scholarhub.balamand.edu.lb/handle/uob/2534
DC FieldValueLanguage
dc.contributor.authorFarhat, Ghada N.en_US
dc.contributor.authorCummings, Steven R.en_US
dc.contributor.authorChlebowski, Rowan T.en_US
dc.contributor.authorParimi, Neetaen_US
dc.contributor.authorCauley, Jane Aen_US
dc.contributor.authorRohan, Thomas E.en_US
dc.contributor.authorHuang, Alison J.en_US
dc.contributor.authorVitolins, Maraen_US
dc.contributor.authorHubbell, F. Allanen_US
dc.date.accessioned2020-12-23T09:15:14Z-
dc.date.available2020-12-23T09:15:14Z-
dc.date.issued2011-
dc.identifier.urihttps://scholarhub.balamand.edu.lb/handle/uob/2534-
dc.description.abstractBackground Endogenous sex hormone levels are associated with risks of breast cancer overall and estrogen receptor (ER)–positive breast tumors; however, their associations with ER-negative tumors remain unclear. Methods In a case–cohort study within the Womens Health Initiative Observational Study among postmenopausal women aged 50–79 years, we examined associations between endogenous testosterone and estradiol levels and the risks of ER-negative and ER-positive breast cancers. Serum levels of bioavailable testosterone and estradiol were assessed at the baseline visit in 317 invasive breast cancer case subjects and in a subcohort of 594 women. Bioavailable sex hormone levels were calculated using the total hormone level and the sex hormone–binding globulin concentration (measured by radioimmunoassays and a chemiluminescent immunoassay, respectively). Cox proportional hazards regression was used for statistical analysis. All statistical tests were two-sided. Result The unadjusted absolute rates of ER-negative breast cancer for testosterone quartiles 1–4 were 0.34, 0.20, 0.23, and 0.21 per 10 000 person-years, respectively. Compared with women in the lowest quartile of testosterone level, those in quartile 2 had a 56% lower risk of ER-negative cancer (hazard ratio [HR] = 0.44, 95% confidence interval [CI] = 0.23 to 0.85), those in quartile 3 had a 45% lower risk (HR = 0.55, 95% CI = 0.30 to 1.01), and those in quartile 4 had a 49% lower risk (HR = 0.51, 95% CI = 0.28 to 0.94), independent of other risk factors. Estradiol level was not associated with ER-negative breast cancer. ER-positive breast cancer risk increased with higher testosterone levels ( Ptrend = .04), but this trend was not statistically significant after adjustment for estradiol ( Ptrend = .15). ER-positive cancer risk was approximately twofold higher in women with estradiol levels in quartiles 2–4 compared with women in quartile 1, independent of risk factors. Conclusion Higher serum level.en_US
dc.format.extent9 p.en_US
dc.language.isoengen_US
dc.subjectTestosteroneen_US
dc.subjectEstradiolen_US
dc.subjectGonadal steroid hormonesen_US
dc.subjectTestosterone measurementen_US
dc.subjectEstrogen receptor negativeen_US
dc.subjectBreast cancer risken_US
dc.subject.lcshCanceren_US
dc.subject.lcshBreast canceren_US
dc.titleSex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancersen_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1093/jnci/djr031-
dc.contributor.affiliationDepartment of Public Healthen_US
dc.description.volume103en_US
dc.description.issue7en_US
dc.description.startpage562en_US
dc.description.endpage570en_US
dc.date.catalogued2018-10-23-
dc.description.statusPublisheden_US
dc.identifier.ezproxyURLhttp://ezsecureaccess.balamand.edu.lb/login?url=https://doi.org/10.1093/jnci/djr031en_US
dc.identifier.OlibID186735-
dc.relation.ispartoftextJournal of the national cancer instituteen_US
dc.provenance.recordsourceOliben_US
Appears in Collections:Department of Public Health
Show simple item record

SCOPUSTM   
Citations

91
checked on Nov 23, 2024

Record view(s)

54
checked on Nov 22, 2024

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.